Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Can CRISPR Make The Jump To Therapeutics?

Mar 20 2014

• By Alex Lash

Related Content

Alnylam’s Comeback: RNAi Developer Partners With Sanofi/Genzyme

Jan 13 2014

Sangamo On A Roll, Clarifies Timelines And Catalysts, Takes On CRISPR

Feb 13 2014

Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level

Jul 01 2007

Related Companies

Gladstone Institutes

University of California San Francisco

University of California, Berkeley

Sangamo Therapeutics, Inc.

Editas Medicine

Stanford University

Harvard University

Rockefeller University

Alnylam Pharmaceuticals Inc.

Merck & Co., Inc.

uniQure N.V.

University of Pennsylvania

Biogen, Inc.

US Department of Health and Human Services

National Institutes of Health

Broad Institute

Bristol Myers Squibb Company

Novartis AG

Genetix Biotherapeutics

University of California San Francisco

Constellation Pharmaceuticals, Inc.

Additional Topics

Europe United States Strategy Business Strategies Innovation Intellectual Property Platform Technologies Research & Development BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window